Head-to-head · Cost-Efficiency Index
Pallas Health vs PrescrYbe
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Pallas Health
Shoppers comfortable paying a quarter at a time who want the whole cost stated before signup, and who are not looking for a month-to-month exit.
Visit Pallas HealthPrescrYbe
Shoppers who want an injection, an oral tablet or a microdose plan priced up front on one page, and who budget by the four-week cycle rather than the month.
Visit PrescrYbeThe verdict
Pallas Health and PrescrYbe tie on the Cost-Efficiency Index at 74/100, so neither wins outright on the numbers, so choose on fit. Pallas Health: Shoppers comfortable paying a quarter at a time who want the whole cost stated before signup, and who are not looking for a month-to-month exit. PrescrYbe: Shoppers who want an injection, an oral tablet or a microdose plan priced up front on one page, and who budget by the four-week cycle rather than the month.
Worth knowing either way: CoreAge Rx is one of our partners and leads our leaderboard, where partners are listed first (Cost-Efficiency Index 94/100). See how it stacks up: CoreAge Rx vs Pallas Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Pallas Health | PrescrYbe |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 74/100 |
| Semaglutide / mo | $199/moAverage — Pallas's own figure for $597 billed every 12 weeks, its only cadence; $139 covers the first 4 weeks | $249Every 4 weeks (compounded injection; oral $279, microdose $179) |
| Tirzepatide / mo | $299/moAverage — Pallas's own figure for $897 billed every 12 weeks, its only cadence; $179 covers the first 4 weeks | $339Every 4 weeks (compounded injection; microdose $179) |
| Semaglutide / yr (modeled) | $2,58713 × 4 wks | $3,23713 charges |
| Tirzepatide / yr (modeled) | $3,88713 × 4 wks | $4,40713 charges |
| Coverage | Most states | All 50 states + DC |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #79 | #81 |
Pallas Health
74/100Where the value is
- Both molecules are priced publicly, with the charged block stated rather than only a monthly average
- A genuinely reduced first cycle — $139 semaglutide and $179 tirzepatide for the first four weeks
- Runs a Spanish-language lander as well as the English site, which most of this field does not
The tradeoffs
- There is no monthly rung. The only cadence is a 12-week block paid up front — $597 or $897 — so the advertised 'per month' figure is arithmetic rather than a payment anyone makes
- A 12-week cycle is 4.33 charges a year, not 4, so a year costs more than four times the block
PrescrYbe
74/100Where the value is
- Five GLP-1 plans are priced on the weight-loss page before any questionnaire: semaglutide injection $249, tirzepatide injection $339, oral semaglutide $279, and microdose semaglutide or tirzepatide at $179
- Offers an oral semaglutide formulation as well as weekly injections
- Names its clinical partner, OpenLoop Health, and says plans are evaluated by board-certified clinicians, with follow-ups to adjust dosing and manage side effects
The tradeoffs
- Every price is charged per four weeks, not per month, so a year is 13 charges: $3,237 for semaglutide injections rather than 12 × $249
- Cancellations must reach support at least 72 hours before the next billing date, and a cycle that has already been charged is not refunded
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.